F16.980
Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder
Clinical Classification Guidelines
Inclusion Terms
- Other hallucinogen-induced anxiety disorder, without use disorder
- Phencyclidine induced anxiety disorder, without use disorder
Medical Intelligence & Overview
Hallucinogen-induced anxiety disorder is a mental health condition that occurs after the use of hallucinogenic substances. Characterized primarily by anxiety symptoms triggered or worsened by hallucinogen use, this disorder can significantly impact a person's emotional well-being. It often manifests without an ongoing substance use disorder, meaning the individual may experience anxiety episodes related to past hallucinogen use or during periods of abstinence. Recognizing and understanding this condition is vital for those affected and their caregivers to ensure appropriate support and management.
Causes & Symptoms
Clinical Causes: Use of hallucinogenic substances such as LSD, psilocybin, peyote, or phencyclidine (PCP). Psychological predisposition, including a history of anxiety or mood disorders. Environmental factors during substance use, such as stressful or unfamiliar settings. Pre-existing mental health conditions that may amplify anxiety symptoms following hallucinogen use. Biological factors, including individual sensitivity to hallucinogens affecting brain chemistry.
Key Symptoms: Persistent or recurrent episodes of intense anxiety. Panic attacks characterized by rapid heartbeat, sweating, trembling, or chest pain. Feelings of apprehension, fear, or impending doom. Visual or auditory hallucinations, especially during anxiety episodes. Difficulties concentrating or a sense of detachment from reality. Physical sensations like gastrointestinal discomfort or dizziness. Trouble sleeping due to heightened anxiety or hallucinations.
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a comprehensive clinical evaluation by a mental health professional. The clinician considers the patient's history of hallucinogen use, the timing of symptoms, and whether symptoms align with the criteria for anxiety disorders. It’s important to rule out other mental health conditions and rule in hallucinogen-induced symptoms. Diagnostic tools may include structured interviews and questionnaires designed to assess substance-related mental health issues. Since this disorder occurs in the context of substance use, understanding the pattern, quantity, and duration of hallucinogen consumption is crucial for accurate diagnosis.
Treatment Protocols: Psychotherapy: Cognitive-behavioral therapy (CBT) can help individuals understand and cope with anxiety and hallucinations. Medication: In some cases, medications such as anxiolytics or antidepressants may be prescribed to control anxiety symptoms. Substance cessation: Support and counseling to reinforce abstinence from hallucinogens and manage cravings. Education and support: Providing information about the effects of hallucinogens and managing expectations for recovery. Stress management techniques: Mindfulness, relaxation exercises, and breathing techniques to reduce anxiety levels. Monitoring: Regular follow-up with healthcare professionals to track progress and adjust treatment plans as needed.
Clinical Advice & FAQs
Billing Guidance
Is F16.980 a billable ICD-10 code?
Yes, F16.980 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F16.980?
Clinical documentation must specify the nature of Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder and any associated comorbidities for accurate reporting.
Cite this Clinical Reference